News

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. Viking Therapeutics and ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.
24/7 Wall St. on MSN10d
Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?
Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...
Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play
According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...
Pharmaceutical Technology22h
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs
NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...